Issues in COVID-19 research and statistical analyses (Part XVIV)
December 9, 2021 The new variant for Omicron is causing a lot of stir around the world. Most of the data analysis conducted thus far has been preliminary and other planned data analyses are taking weeks in order to understand the potential severity of the variant and...
Issues in COVID-19 research and statistical analyses (Part XVIII)
At home Antigen tests statistical results November 24, 2021 Antigen tests for SARS-CoV-2 are back and are pending more approvals by the current administration. If so, they may be used more often and more frequently to help people get back to a more normal lifestyle....
Issues in COVID-19 research and statistical analyses (Part XVII)
Pfizer anti-viral November 10, 2021 Pfizer, similar to Merck, has announced the efficacy of their anti-viral drug called PAXLOVID against SARS-CoV-2. The reported 89% efficacy against serious disease and 100% efficacy against death and they are making headlines....
Issues in COVID-19 research and statistical analyses (Part XVI)
Mix and match boosters October 27, 2021 In recent news, the CDC/FDA are approving booster shots not only for Pfizerã but also for Modernaã and Johnson & Johnsonã, and even mixing and matching these boosters, but is there any science behind this...
Issues in COVID-19 research and statistical analyses (Part XV)
Antivirals EUA October 13, 2021 In recent news, Merck and Ridgeback has been hailing an oral anti-viral drug against Sars-CoV-2 that can cut the hospitalization and death rates in half according to their news posted on Oct 1, 2021 on their website. Apparently, the...
Issues in COVID-19 research and statistical analyses (Part XIV)
Booster shots for all vaccines September 30, 2021 The Centers for Disease Control and Prevention (CDC) has been promoting booster shots most recently for all vaccines for COVID-19: Pfizer, Moderna, and Johnson & Johnson. However, the Food & Druge...
Issues in COVID-19 research and statistical analyses (Part XIII)
J&J Booster shots A more recent controversy has come up with the Johnson & Johnson (J&J) vaccine perhaps needing a booster shot sooner than the mRNA based vaccines for COVID-19. A current problem is there is no verifiable data or rather limited...
Issues in COVID-19 research and statistical analyses (Part XII)
A lot of controversy has come up with the boosters for the COVID-19 vaccines and efficacy. The Israeli study on efficacy comparing people vaccinated last year to people vaccinated this year seemed to indicate the efficacy was waning over time.
Issues in COVID-19 research and statistical analyses (Part XI)
Recently, there has been a lot of news about COVID-19 research tied to the studies conducted in Israel since they have such a high rate of vaccination and since they themselves have conducted several analyses which are very timely for understanding the changes in efficacy of the vaccines, mainly of the Pfizer and Moderna mRNA ones.
Issues in COVID-19 research and statistical analyses (Part X)
As we have heard or know, COVID-19 research, especially in early 2020, was filled with observational studies, many of which were potentially underpowered, but it turns out, even randomized controlled trials. Sample size estimation went out the window. Even Lee...